Generic drug utilisation on the General Medical Services (GMS) scheme in 2001

Irish Medical Journal

Volumn 96, Issue 6, 2003, Pages 176-179

  Tilson, L ^a   McGowan, B ^a   Ryan, M ^a   Barry, M ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTOPRIL; AMOLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ATECOR; ATENOGEN; ATENOLOL; BECLOMETASONE DIPROPIONATE; CAPTOPRIL; CAPTOR; CARDOX; CLAVAMEL; DICLAC; DICLO; DICLOFENAC; DICLOMEL; FLUOXETINE; GENERIC DRUG; GERMENTIN; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; LISINOPRIL; NIMESULIDE; NORZAC; RANITIDINE; RANOPINE; SALBUTAMOL; SORMON; VENTAMOL;

ARTICLE; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG UTILIZATION; MEDICAL SERVICE; PRESCRIPTION; QUANTITATIVE ANALYSIS; ECONOMICS; HUMAN; IRELAND; PUBLIC HEALTH; STATISTICS; TIME;

DRUGS, GENERIC; HUMANS; IRELAND; NATIONAL HEALTH PROGRAMS; PRESCRIPTIONS, DRUG; TIME FACTORS;

EID: 0141706936     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. General Medical Services Payments Board, Report for the year ended 31st December. 2001:1-54.
2. General Medical Services Payments Board, Financial and Statistical Analysis of Claims and Payments. 2001:6.
3. Department of Health, U., Prescriptions dispensed in the community. Statistics for 1991 to 2001: England. Statistical Bulletin, www.doh.gov.uk, 2002.
4. McGettigan, P., et al., Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: Prescribers'concerns. Irish Medical Journal, 1997. 90(4):146-147.
5. Griffin, J., An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996. Pharmacoeconomics, 1996. 10(3):210-224.
6. Comptroller and Auditor General, Prescribing practices and the development of general practice services. Stationary Office: Dublin, 1997:1-28.
7. Bloor, K. and N. Freemantle, Lessons from international experience in controlling pharmaceutical expenditure: influencing doctors. BMJ, 1996. 312:1525-1527.
8. Walley, T., et al., Effects of a monetary incentive on primary care prescribing in Ireland: Changes in prescribing patterns in one health board 1990-1995. Pharmacoepidemiology and Drug Safety, 2000. 9:591-598.
9. Murphy, M., Review of Indicative Drug Target Saving scheme. 1997, UCC: Cork. 191.
10. Harris, C. and G. Scrivener, Fundholders' prescribing costs: the first five years. BMJ, 1996. 313:1531-1534.
11. Anonymous, Use more generics,Danish minister says. Scrip, 2002. 2767:7.
12. Anonymous, Major change ahead in Sweden. Scrip, 2002. 2771:5.
13. Anonymous, Finland plans generic substitution. Scrip, 2002. 2788:7.
14. McManus, P., et al., Impact of the minimum pricing policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia. Pharmacoepidemiology and Drug Safety, 2001. 10(4):295-300.
15. McGavock, H., Generic substitution - issues relating to the Australian experience. Pharmacoepidemiology and Drug Safety, 2001. 10:555-556.